Lupin Pharmaceuticals Inc. and Eugia US LLC, subsidiaries of Lupin and Aurobindo Pharma respectively, are recalling products from the US market due to manufacturing issues, as per the USFDA. Lupin is recalling Cefixime for Oral Suspension due to failed content uniformity specifications, while Eugia is recalling Dexamethasone Sodium Phosphate and Eptifibatide injections for failed impurities/degradation specifications. These Class II and Class III recalls indicate potential health risks ranging from reversible to unlikely adverse consequences.